The interferon-α2b gene in Japanese patients with chronic viral hepatitis who developed antibodies after treatment with recombinant interferon-α2a

DNA was extracted from leucocytes of 23 Japanese patients with chronic viral hepatitis who received treatment with recombinant interferon-alpha 2a (IFN-alpha 2a) and nine healthy controls, as well as eight human cell lines of Caucasian or African origin. A part of the gene encoding IFN-alpha 2 was amplified by polymerase chain reaction and the sequence of nucleotides 1-231 was determined. Interferon-alpha 2a, -alpha 2b and -alpha 2c genes were tested for in five clones each from a patient or control, or a cell line, based on adenine or guanine at nucleotide positions 68 and 101. The IFN-alpha 2b gene was detected in all 160 clones from 23 Japanese patients and nine controls, but the IFN-alpha 2a or -alpha 2c gene was not found in any. Of five cell lines derived from Caucasians, four exhibited only the IFN-alpha 2b gene, while the remaining one exhibited both IFN-alpha 2a and -alpha 2b genes. Of three cell lines derived from Africans, one each showed only the IFN-alpha 2b or -alpha 2c gene, and the remaining one both IFN-alpha 2b and -alpha 2c genes. The 23 patients with the IFN-alpha 2b gene and chronic viral hepatitis included 10 who developed antibodies against IFN after treatment with recombinant IFN-alpha 2a. These results indicated a distinct geographical distribution of the three IFN-alpha 2 genes, and suggested the use of a recombinant IFN-alpha 2 preparation in agreement with the IFN-alpha 2 gene possessed by the recipient to avoid antibody responses.     

Development of a Compact, Highly Efficient, Totally Implantable Motor–Driven Assist Pump System

Abstract: We have developed a compact, highly efficient, totally implantable assist pump system, which consists of a motor–driven assist pump and a transcutaneous energy and optical information transmission system. The motor–driven assist pump consists of ad. c. brushless motor and a specially designed miniature ball screw. A magnetic coupling mechanism between the blood pump and an actuator provides active blood filling via mild suction force. The controller consists of a PID follow–up controller using an 8–bit one–chip microcomputer. The volume of the pump is 350 ml, and its controller is 210 ml. Pump outflow of 5. 8 L/min was obtained against a mean afterload of 100 mm Hg. The pump showed a high efficiency rate and good durability. An efficiency rate of 19–21% (pump output/motor input) was obtained during 87 days of continuous pumping. No mechanical trouble occurred for an accumulated period of 6 months.     

In Vitro Biological Activity of an Insulin-like Active Substance Extracted from the Tumor Tissue of a Patient with Primary Liver Cell Carcinoma Associated with Severe Spontaneous Hypoglycemia

Biological activity of an insulin-like active substance, extractedfrom the tissue of a tumor tissue of a patient with primaryliver cell carcinoma associated with severe spontaneous hypoglycemia,was studied in vitro. The substance was acid insoluble. It stimulatedglucose uptake and glucose oxidation by rat muscle and adiposetissue, and these effects were not suppressed by anti-insulinantibody. It stimulated glycogen synthesis in rat muscle tissuebut not in adipose tissue. Oxidation of glucose C-1 by adiposetissue was enhanced strongly by the substance, but it had noeffect on glucose C-6 oxidation. The biological activity ofthe substance resembled that of non-suppressible insulin-likeactivity-precipitated (NSILA-P) rather than that of pancreaticinsulin or nonsuppressible insulin-like activity-soluble (NSILA-S).     

In vitro production of bilirubin photoisomers by light irradiation using neoBLUE

BACKGROUND: The light-emitting diode is used as one of the new light sources for phototherapy. NeoBLUE (Atom Medical, Tokyo, Japan) incorporates blue light-emitting diodes for the treatment of neonatal hyperbilirubinemia. The authors compared the in vitro efficacy of neoBLUE with conventional phototherapy devices. METHODS: The three light devices used included neoBLUE and two conventional phototherapy devices with six blue-white (BW) or six green (GR) fluorescent tubes. A bilirubin/human serum albumin solution (15 mg/dL) in 200 x 300 mm elliptical bag was irradiated with each three light device. The average light intensity of neoBLUE, BW and GR was 22.5, 10.2 and 2.6 microW/cm(2) per nm, respectively, for the irradiated area. Bilirubin photoisomers and native bilirubin were measured by high-performance liquid chromatography. RESULTS: In neoBLUE, BW and GR, the respective production rate of cyclobilirubin was 6.0, 3.7 and 3.9 x 10(-2) mg/dL/min, and the respective (4Z, 15E)-bilirubin/(4Z, 15Z)-bilirubin ratio after irradiation was 0.44, 0.33 and 0.12; the (4Z, 15Z)-bilirubin reduction rate at 20 min after irradiation was 60, 68 and 82%, respectively. The reduction rate of (4Z, 15Z)-bilirubin correlated with the (4Z, 15E)-bilirubin/(4Z, 15Z)-bilirubin ratio. CONCLUSION: Phototherapy using the neoBLUE under high level may be clinically more effective than therapy using the conventional light source from the results of the production rate of cyclobilirubin.